Find a trial

Trofuse-010

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Locations Mount Alvernia

Diagnosis Breast cancer

RASolve301

Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Unresectable or Metastatic NSCLC Harboring RAS Mutations.

Locations Mount Alvernia

Diagnosis Lung cancer

Lunar-2

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Locations Mount Alvernia, Farrer Park

Diagnosis Lung cancer

TROPION-Lung15

A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment

Locations Farrer Park, Mount Alvernia

Diagnosis Lung cancer

BAY 3713372

A study of PRMT5 inhibitor BAY 3713372 in participants with MTAP-deleted solid tumors.

Locations Mount Alvernia, Farrer Park

Diagnosis Lung cancer, Advanced solid tumours, Pancreatic cancer

pionERA

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Locations Gleneagles, Farrer Park

Diagnosis Breast cancer